Endocrinology AdvisorOrexigen Terminates Required Study for Diet Drug ContraveWall Street JournalOrexigen Therapeutics said Tuesday it has terminated a required cardiovascular outcomes trial of its obesity drug Contrave, after prematurely releasing interim study results in March. The company noted that the study isn't being terminated because of the ...Heart Benefit For Orexigen Drug Nearly Vanishes With New DataForbesContrave CV Outcomes Study Terminated EarlyMonthly Prescribing ReferenceLight Study Termination 'Positive' for Orexigen (OREX), Leerink Partners SaysStreetInsider.comAkron Beacon Journal (blog)all 8 news articles »
Orexigen Terminates Required Study for Diet Drug Contrave
Rating: 4.5
Diposkan Oleh: Unknown
